Deborah Mascalzoni joined CRB in April 2013. She holds a PhD in Bioethics from the Faculty of Law at Bologna University and has worked extensively on ELSI issues related to biobank and registry research, especially the population based CHRIS project at the Center of Biomedicine, European Academy (EURAC).
Deborah Mascalzoni has been teaching ethics at the 'Claudiana' University of Roma in Bolzano. She is a member of the Ethical board of South Tyrol and the local health system ethical board of Bolzano as well as the Telethon Advisory Board. She is involved in the WIKI platform of BBMRI.IT, a member of the BRIF project and a member of the ethical group of the International Genetic Epidemiological Society (IGES). Her main research interests are genetics and new technologies, informed consent, patient communication, privacy & data sharing and the role of stakeholders in medicine.
Phone: +46 18 471 62 32
Recently in the media
- International Rare Diseases Research Consortium (IRDiRC) - The principles for sharing: BBMRI-ERIC Newsflash 2015-08-27
Rare disease research
RD-Connect is a 7th framework project that aims to build an integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research. We address the ethical, legal and social issues (ELSI).
Arthritis risk communication
Euro-TEAM is a 7th framework programme aiming towards early diagnosis and biomarker validation in arthritis management. We are working with risk communication.
ELSI-Service for BBMRI.se
We run the ELSI-Services for BBMRI.se (BioBanking and Molecular Resource Infrastructure of Sweden): a national effort for efficient and automated collection of biological material funded by the Swedish Research Council.
Arthritis: Early treatment
The development of new therapeutic agents against Rheumatoid arthritis (RA) and RA-like diseases requires a dynamic interaction between studies in humans and in animal models of disease.
Citizen health in genomics
We are part of CHIP ME, a community of researchers and stakeholders to promote public-private initiatives in public health genomics.
Biobanks and registries in research
We aim for a biobank and registry management that satisfies ethical and legal demands from the research community, the public and the individual.
- BMC Medical Ethics, vol. 18 DOI Download fulltext
Legal issues in governing genetic biobanks: the Italian framework as a case study for the implications for citizen's health through public-private initiatives..(2017). Journal of Community Genetics DOI
- Biopreservation and Biobanking, vol. 14, ss. 241-248 DOI Download fulltext
Improving the informed consent process in international collaborative rare disease research: effective consent for effective research.(2016). European Journal of Human Genetics, vol. 24, ss. 1248-1254 DOI Download fulltext
'You should at least ask'. The expectations, hopes and fears of rare disease patients on large-scale data and biomaterial sharing for genomics research..(2016). European Journal of Human Genetics, vol. 24, ss. 1403-1408 DOI
- Frontiers in Bioscience, vol. 21, ss. 719-43
- Hypertension, vol. 67, ss. 681-687 DOI
- European Journal of Human Genetics, vol. 23, ss. 721-728 DOI Download fulltext
The Cooperative Health Research in South Tyrol (CHRIS) study: rationale, objectives, and preliminary results.(2015). Journal of Translational Medicine, vol. 13 DOI
Biobank and registry ethics & law
For many years, researchers at CRB have provided constructive advise on how to deal with ethical and legal aspects of research using human tissue material and personal data. We have collaborated with biomedical scientists and published our findings in peer reviewed journals. As a summary of this research we have compiled a list of publications with abstracts. We have grouped them thematically to help you find the ones you might be interested in reading. Our publications deal with ethical frameworks and policy, regulatory aspects of biobank and registry research, informed consent, ethical review, integrity concerns, trust, genetic testing, indicental findings, commercialization, public and patient perceptions, rare diseases, children & biobanks & genetics, and biobank studies.